MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

Bruker Corp

Gesloten

SectorGezondheidszorg

34.8 0.35

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

34.39

Max

35.99

Belangrijke statistieken

By Trading Economics

Inkomsten

-13M

4.2M

Verkoop

-4M

797M

K/W

Sectorgemiddelde

59.385

35.739

Dividendrendement

0.64

Winstmarge

0.527

Werknemers

11,396

EBITDA

-21M

68M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+28.34% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.64%

3.08%

Volgende Winsten

4 nov 2025

Volgende dividenddatum

3 okt 2025

Volgende Ex Dividend datum

1 dec 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-551M

4.7B

Vorige openingsprijs

34.45

Vorige sluitingsprijs

34.8

Nieuwssentiment

By Acuity

9%

91%

7 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Bruker Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 sep 2025, 22:10 UTC

Belangrijke Marktbewegers

Bruker Shares Fall on Convertible Share Offering Aimed at Debt Repayment

Peer Vergelijking

Prijswijziging

Bruker Corp Prognose

Koersdoel

By TipRanks

28.34% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 44.56 USD  28.34%

Hoogste 60 USD

Laagste 38 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bruker Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

6

Buy

4

Hold

0

Sell

Technische score

By Trading Central

38.97 / 40.73Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

7 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bruker Corp

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
help-icon Live chat